Atricure (ATRC) 18.86 $ATRC
AtriCure Up 21.6% Since SmarTrend Uptrend Call (ATRC)
Comtex SmarTrend(R) - Wed Feb 11, 9:59AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 4 months, AtriCure has returned 21.61% as of today's recent price of $18.94.
ATRC: 18.86 (+0.04)
Lombard Medical Appoints Michael H. Carrel to Its Board of Directors
GlobeNewswire - Wed Feb 11, 9:55AM CST
Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that Michael H. Carrel has been appointed to the Company's Board of Directors.
EVAR: 5.47 (-0.07), ATRC: 18.86 (+0.04)
AtriCure Has Returned 24.3% Since SmarTrend Recommendation (ATRC)
Comtex SmarTrend(R) - Wed Feb 04, 9:19AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 4 months, AtriCure has returned 24.30% as of today's recent price of $19.36.
ATRC: 18.86 (+0.04)
AtriCure reports February 23
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:45PM CST
ATRC: 18.86 (+0.04)
AtriCure to Announce Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Mon Feb 02, 3:02PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will release its financial results for the fourth quarter and full year 2014 on Monday, February 23, 2015.
ATRC: 18.86 (+0.04)
AtriCure Shares Up 28.3% Since SmarTrend's Buy Recommendation (ATRC)
Comtex SmarTrend(R) - Tue Jan 27, 5:00PM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 4 months, AtriCure has returned 28.28% as of today's recent price of $19.98.
ATRC: 18.86 (+0.04)
Shares of ATRC Up 28.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jan 20, 10:58AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 3 months, AtriCure has returned 28.09% as of today's recent price of $19.95.
ATRC: 18.86 (+0.04)
AtriCure to Present at the Leerink Global Healthcare Conference
Business Wire - Mon Jan 19, 3:05PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Thursday, February 12, 2015. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation on the Investors page of AtriCure's corporate website at www.atricure.com.
ATRC: 18.86 (+0.04)
AtriCure Is Successfully Using Marketing And Training To Drive Revenue
Stephen Simpson, CFA - at Seeking Alpha - Thu Jan 15, 4:07PM CST
BSX: 14.98 (+0.24), JNJ: 99.62 (+1.18), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65), ATRC: 18.86 (+0.04)
Execs on the move at AtriCure
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 3:22PM CST
ATRC: 18.86 (+0.04)
Douglas Seith Assumes the Role of AtriCure Chief Operating Officer; Andy Wade Promoted to Senior Vice President
Business Wire - Wed Jan 14, 3:05PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that Douglas Seith will assume the role of Chief Operating Officer. Mr. Seith will now be responsible for all global commercial organizations as well as education and clinical science programs. The company also announced that Andy Wade has been promoted to Senior Vice President and Chief Financial Officer.
BSX: 14.98 (+0.24), ATRC: 18.86 (+0.04)
AtriCure reports preliminary results and 2015 outlook
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 1:58PM CST
ATRC: 18.86 (+0.04)
AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2014 Issues 2015 Guidance
Business Wire - Mon Jan 12, 7:30AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation ("Afib"
and Left Atrial Appendage Management ("LAAM" , today announced preliminary financial results for fourth quarter and full year 2014 and issued 2015 financial guidance.
ATRC: 18.86 (+0.04)
27.1% Return Seen to Date on SmarTrend AtriCure Call (ATRC)
Comtex SmarTrend(R) - Tue Jan 06, 9:18AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 3 months, AtriCure has returned 27.13% as of today's recent price of $19.80.
ATRC: 18.86 (+0.04)
InsiderInsights.com Daily Round Up 1/2/15: IFT, OPK, SNCR, GPRE
InsiderInsights - at Seeking Alpha - Mon Jan 05, 2:55AM CST
ATRC: 18.86 (+0.04), MAR: 79.39 (+0.37), SHLD: 35.70 (+2.32), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), WIW: 11.29 (unch), PLUS: 80.17 (-0.21), OCIP: 16.27 (-0.46), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), AFG: 62.89 (+0.08), CFNL: 19.32 (+0.02), GPRE: 25.50 (-0.56), BDN: 16.45 (-0.17), NMBL: 23.19 (+0.81), AAPL: 127.08 (+0.62), ALCO: 45.40 (+1.44), IFT: 6.41 (+0.04)
Uptrend Call Working As AtriCure Stock Rises 21.0% (ATRC)
Comtex SmarTrend(R) - Thu Dec 18, 9:20AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 2 months, AtriCure has returned 21.03% as of today's recent price of $18.85.
ATRC: 18.86 (+0.04)
Volcano Acquired by Royal Philips for $1.2B: What Wall Street's Saying
at The Street - Wed Dec 17, 2:20PM CST
Volcano Corp. shares surged more than 50% on Wednesday after Royal Philips agreed to acquire the medical technology company for $1.2 billion.
BSX: 14.98 (+0.24), SPNC: 33.69 (-0.06), ABT: 46.09 (+0.87), PHG: 28.93 (-0.07), MDT: 75.26 (+0.33), TRIV: 10.07 (+0.15), VOLC: 17.98 (+0.03), STJ: 67.48 (+0.65), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09), ELGX: 14.51 (+0.21), ATRC: 18.86 (+0.04), NVDQ: 15.12 (+0.51)
AtriCure Up 21.6% Since SmarTrend Uptrend Call (ATRC)
Comtex SmarTrend(R) - Wed Feb 11, 9:59AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 4 months, AtriCure has returned 21.61% as of today's recent price of $18.94.
ATRC: 18.86 (+0.04)
Lombard Medical Appoints Michael H. Carrel to Its Board of Directors
GlobeNewswire - Wed Feb 11, 9:55AM CST
Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that Michael H. Carrel has been appointed to the Company's Board of Directors.
EVAR: 5.47 (-0.07), ATRC: 18.86 (+0.04)
AtriCure Has Returned 24.3% Since SmarTrend Recommendation (ATRC)
Comtex SmarTrend(R) - Wed Feb 04, 9:19AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 4 months, AtriCure has returned 24.30% as of today's recent price of $19.36.
ATRC: 18.86 (+0.04)
AtriCure reports February 23
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:45PM CST
ATRC: 18.86 (+0.04)
AtriCure to Announce Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Mon Feb 02, 3:02PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will release its financial results for the fourth quarter and full year 2014 on Monday, February 23, 2015.
ATRC: 18.86 (+0.04)
AtriCure Shares Up 28.3% Since SmarTrend's Buy Recommendation (ATRC)
Comtex SmarTrend(R) - Tue Jan 27, 5:00PM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 4 months, AtriCure has returned 28.28% as of today's recent price of $19.98.
ATRC: 18.86 (+0.04)
Shares of ATRC Up 28.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jan 20, 10:58AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 3 months, AtriCure has returned 28.09% as of today's recent price of $19.95.
ATRC: 18.86 (+0.04)
AtriCure to Present at the Leerink Global Healthcare Conference
Business Wire - Mon Jan 19, 3:05PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Thursday, February 12, 2015. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast and replay of the presentation will be available for 30 days following the presentation on the Investors page of AtriCure's corporate website at www.atricure.com.
ATRC: 18.86 (+0.04)
AtriCure Is Successfully Using Marketing And Training To Drive Revenue
Stephen Simpson, CFA - at Seeking Alpha - Thu Jan 15, 4:07PM CST
BSX: 14.98 (+0.24), JNJ: 99.62 (+1.18), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65), ATRC: 18.86 (+0.04)
Execs on the move at AtriCure
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 3:22PM CST
ATRC: 18.86 (+0.04)
Douglas Seith Assumes the Role of AtriCure Chief Operating Officer; Andy Wade Promoted to Senior Vice President
Business Wire - Wed Jan 14, 3:05PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that Douglas Seith will assume the role of Chief Operating Officer. Mr. Seith will now be responsible for all global commercial organizations as well as education and clinical science programs. The company also announced that Andy Wade has been promoted to Senior Vice President and Chief Financial Officer.
BSX: 14.98 (+0.24), ATRC: 18.86 (+0.04)
AtriCure reports preliminary results and 2015 outlook
Seeking Alpha - at Seeking Alpha - Mon Jan 12, 1:58PM CST
ATRC: 18.86 (+0.04)
AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2014 Issues 2015 Guidance
Business Wire - Mon Jan 12, 7:30AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation ("Afib"
and Left Atrial Appendage Management ("LAAM" , today announced preliminary financial results for fourth quarter and full year 2014 and issued 2015 financial guidance. ATRC: 18.86 (+0.04)
27.1% Return Seen to Date on SmarTrend AtriCure Call (ATRC)
Comtex SmarTrend(R) - Tue Jan 06, 9:18AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 3 months, AtriCure has returned 27.13% as of today's recent price of $19.80.
ATRC: 18.86 (+0.04)
InsiderInsights.com Daily Round Up 1/2/15: IFT, OPK, SNCR, GPRE
InsiderInsights - at Seeking Alpha - Mon Jan 05, 2:55AM CST
ATRC: 18.86 (+0.04), MAR: 79.39 (+0.37), SHLD: 35.70 (+2.32), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), WIW: 11.29 (unch), PLUS: 80.17 (-0.21), OCIP: 16.27 (-0.46), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), AFG: 62.89 (+0.08), CFNL: 19.32 (+0.02), GPRE: 25.50 (-0.56), BDN: 16.45 (-0.17), NMBL: 23.19 (+0.81), AAPL: 127.08 (+0.62), ALCO: 45.40 (+1.44), IFT: 6.41 (+0.04)
Uptrend Call Working As AtriCure Stock Rises 21.0% (ATRC)
Comtex SmarTrend(R) - Thu Dec 18, 9:20AM CST
SmarTrend identified an Uptrend for AtriCure (NASDAQ:ATRC) on October 14th, 2014 at $15.58. In approximately 2 months, AtriCure has returned 21.03% as of today's recent price of $18.85.
ATRC: 18.86 (+0.04)
Volcano Acquired by Royal Philips for $1.2B: What Wall Street's Saying
at The Street - Wed Dec 17, 2:20PM CST
Volcano Corp. shares surged more than 50% on Wednesday after Royal Philips agreed to acquire the medical technology company for $1.2 billion.
BSX: 14.98 (+0.24), SPNC: 33.69 (-0.06), ABT: 46.09 (+0.87), PHG: 28.93 (-0.07), MDT: 75.26 (+0.33), TRIV: 10.07 (+0.15), VOLC: 17.98 (+0.03), STJ: 67.48 (+0.65), THOR: 40.01 (+0.54), HTWR: 88.18 (-0.09), ELGX: 14.51 (+0.21), ATRC: 18.86 (+0.04), NVDQ: 15.12 (+0.51)
